Back to Search
Start Over
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
- Source :
-
Journal of endocrinological investigation [J Endocrinol Invest] 2022 Mar; Vol. 45 (3), pp. 583-595. Date of Electronic Publication: 2021 Oct 19. - Publication Year :
- 2022
-
Abstract
- Purpose: To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI).<br />Methods: In this open label, parallel randomized clinical trial, 66 women with PCOS (33 normal-weight and 33 overweight/obese) were randomized to either MI (4 g/day) or MET (1500 mg/day) for a period of 6 months. Serum concentration of adiponectin, hormonal and metabolic laboratory outcomes and clinical assessment of BMI, body composition and Ferriman-Gallwey score (FG score) were evaluated before and after treatment.<br />Results: After the 6-month intervention, comparison between MET and MI in time to treatment analysis showed no significant differences between the two treatments for all analyzed parameters. Only borderline significantly lower AUC glucose was found in the MET group in comparison to the MI group (p = 0.071). The main effect of treatment was shown for glucose concentration at 120 min OGTT (p = 0.032) and testosterone (p = 0.002). The main effect of time was shown for body mass (p = 0.004), waist circumference (p < 0.001), BMI (p = 0.003), body fat mass (p = 0.001), adiponectin (p = 0.020), fasting glucose (p = 0.001), testosterone (p = 0.015), SHBG (p = 0.013), 17OH progesterone (p = 0.008), LH (p = 0.004) and estradiol (p = 0.014).<br />Conclusion: Our study showed similar effects of MET and MI on BMI, body composition, hormonal profile, metabolism of glucose and insulin, and adiponectin level. The two insulin sensitizers, MET and MI, were useful in reducing BMI and improving body composition without significant differences between the two treatments in PCOS women.<br />Trial Registration: ISRCTN13199265. Trial registration date: 14.04.2021. (ISRCTN Registry), retrospectively registered.<br /> (© 2021. Italian Society of Endocrinology (SIE).)
- Subjects :
- Adult
Blood Glucose analysis
Body Composition
Body Mass Index
Female
Humans
Hypoglycemic Agents administration & dosage
Insulin blood
Insulin Resistance
Treatment Outcome
Vitamin B Complex administration & dosage
Adiponectin blood
Gonadal Steroid Hormones blood
Inositol administration & dosage
Metformin administration & dosage
Obesity complications
Obesity diagnosis
Obesity metabolism
Polycystic Ovary Syndrome complications
Polycystic Ovary Syndrome diagnosis
Polycystic Ovary Syndrome drug therapy
Polycystic Ovary Syndrome metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1720-8386
- Volume :
- 45
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of endocrinological investigation
- Publication Type :
- Academic Journal
- Accession number :
- 34665453
- Full Text :
- https://doi.org/10.1007/s40618-021-01691-5